Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) shares gapped up before the market opened on Monday . The stock had previously closed at $133.11, but opened at $133.44. Alexion Pharmaceuticals shares last traded at $136.42, with a volume of 695,495 shares trading hands.

A number of research analysts have recently commented on ALXN shares. Morgan Stanley reissued an “overweight” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 29th. Citigroup Inc. raised Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $154.00 price target on the stock in a report on Monday, June 27th. Royal Bank Of Canada started coverage on Alexion Pharmaceuticals in a report on Tuesday, July 12th. They set an “outperform” rating and a $188.00 price target on the stock. Jefferies Group reissued a “hold” rating and set a $140.00 price target (down from $159.00) on shares of Alexion Pharmaceuticals in a report on Monday, July 25th. Finally, Credit Suisse Group AG raised Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and lowered their price target for the company from $186.00 to $165.00 in a report on Monday, July 11th. They noted that the move was a valuation call. Seven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $184.27.

The firm has a 50 day moving average price of $126.99 and a 200-day moving average price of $138.27. The stock has a market capitalization of $30.51 billion and a P/E ratio of 341.88.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The firm earned $753 million during the quarter, compared to the consensus estimate of $743.18 million. The firm’s revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.44 EPS. On average, analysts anticipate that Alexion Pharmaceuticals Inc. will post $4.65 earnings per share for the current fiscal year.

In related news, Director Leonard Bell sold 1,010 shares of the company’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $138,511.40. Following the completion of the sale, the director now owns 405,289 shares in the company, valued at $55,581,333.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Heidi L. Wagner sold 222 shares of the company’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $30,445.08. Following the completion of the sale, the senior vice president now owns 32,115 shares of the company’s stock, valued at approximately $4,404,251.10. The disclosure for this sale can be found here.

A number of large investors recently added to or reduced their stakes in ALXN. Calvert Investment Management Inc. increased its stake in Alexion Pharmaceuticals by 21.7% in the fourth quarter. Calvert Investment Management Inc. now owns 10,051 shares of the biopharmaceutical company’s stock worth $1,917,000 after buying an additional 1,790 shares in the last quarter. American International Group Inc. increased its stake in Alexion Pharmaceuticals by 1.2% in the fourth quarter. American International Group Inc. now owns 98,141 shares of the biopharmaceutical company’s stock worth $18,720,000 after buying an additional 1,203 shares in the last quarter. KBC Group NV increased its stake in Alexion Pharmaceuticals by 82.0% in the fourth quarter. KBC Group NV now owns 40,298 shares of the biopharmaceutical company’s stock worth $7,687,000 after buying an additional 18,160 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Alexion Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 289,785 shares of the biopharmaceutical company’s stock worth $55,277,000 after buying an additional 6,189 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in Alexion Pharmaceuticals by 563.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 113,751 shares of the biopharmaceutical company’s stock worth $21,698,000 after buying an additional 96,615 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.